Cargando…
EGFR外显子20插入突变型NSCLC治疗的研究进展
Lung cancer has become one of the most dangerous cancers to human health and the mortality rate is the highest among all the causes of cancer death. Non-small cell lung cancer (NSCLC) accounts for about 80%-85% of lung cancer. Chemotherapy is the main treatment for advanced NSCLC, but the 5-year sur...
Autores principales: | XU, Meiyi, LUO, Jiawei, XU, Ruilian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Editorial board of Chinese Journal of Lung Cancer
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10033241/ https://www.ncbi.nlm.nih.gov/pubmed/36872053 http://dx.doi.org/10.3779/j.issn.1009-3419.2023.101.05 |
Ejemplares similares
-
EGFR外显子20插入突变阳性NSCLC治疗的临床研究进展
Publicado: (2022) -
EGFR基因20外显子插入突变在非小细胞肺癌的研究及其进展
Publicado: (2020) -
非小细胞肺癌EGFR外显子20插入突变检测和靶向药物研究进展
por: WANG, Yulu, et al.
Publicado: (2023) -
MET 14外显子跳跃突变NSCLC靶向治疗专家共识
Publicado: (2023) -
MET 14外显子跳跃突变在非小细胞肺癌中的研究进展
Publicado: (2018)